Methods

Study Subjects
The discovery cohort included patients in the prospective Vanderbilt Cardiac Surgery Registry who underwent CABG without concurrent valve surgery from November 1999 until November 2004. The validation cohort included patients in the prospective CABG Genomics Program at Brigham and Women's Hospital and the Texas Heart Institute. Patients who had CABG without valve surgery after August 2001 were included in the analysis. All analyses were restricted to self-reported white patients to minimize genetic heterogeneity. Only patients who were in sinus rhythm at the time of surgery were included in the analysis. The study complies with the Declaration of Helsinki, the Institutional Review Boards at each participating institution approved the registries, and all patients gave written informed consent.
Patient demographics, biometrics, clinical comorbidities, and other variables were prospectively entered into both registries using standard definitions. PoAF, the primary study end point, was defined as electrocardiographically documented AF, as assessed by inpatient telemetry and 12-lead ECGs during the index hospitalization after surgery. To be considered a case, the episode of AF needed to be of sufficient duration to require specific therapy. Otherwise, there was no specific minimum duration of AF necessary to be considered a case.
Genotyping
Genotyping was performed for 13 single nucleotide polymorphisms (SNPs) associated with prevalent AF in large genome-wide association studies [12] [13] [14] : rs13376333 and rs6666258 at 1q21; rs3903239 at 1q24; rs2200733, rs10033464, and rs6817105 at 4q25; rs3807989 at 7q31; rs10821415 at 9q22; rs10824026 at 10q22; rs1152591 at 14q23; rs7164883 at 15q24; and rs2106261 and rs7193343 at 16q22. Genotyping was performed using the Sequenom platform (San Diego, CA).
Risk Model for PoAF
Multivariable logistic regression using age, sex, previous AF, diabetes mellitus, hypertension, left ventricular ejection fraction, PR interval, smoking, chronic obstructive pulmonary disease, and use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins, aspirin, and cyclooxygenase-2 inhibitors was performed to predict PoAF in the discovery cohort. Age, previous AF, and PR interval were highly significant and carried forward in further analyses. Diabetes mellitus, hypertension, left ventricular ejection fraction<40%, preoperative use of β-blockers, and postoperative use of β-blockers were nonsignificant in the initial model but were included in further analyses, as they were previously established as PoAF risk factors. 1, 4, 7 The combined clinical and genetic model included all of the clinical factors plus rs13376333 (T allele), rs6666258 (C), rs3903239 (A), rs2200733 (T), rs3807989 (A), rs10821415 (A), rs10824026 (G), rs1152591 (A), rs2106261 (A), and rs7193343 (C), using an additive model (0, 1, or 2 copies of the minor allele) for each SNP. Genotyping for the other 3 SNPs failed quality control measures, and, therefore, these were not included in the analysis. Receiver operator characteristic (ROC) curves were generated for the clinical-only and combined clinical/genetic models in both cohorts. A calibration curve was generated to assess the performance of the combined clinical/genetic model in the validation cohort. 16 For this, grouped predicted probabilities for the development of PoAF were plotted against observed probabilities within each group and a curve was fit for the grouped observations. For an ideal prediction model, the curve would be a straight line with a slope equal to 1. The distribution of the grouped observations and the fitted curve provide information about how the model performs for different predicted probabilities.
We derived a simple weighted risk score for PoAF using clinical data from the discovery cohort. Based on the magnitude of odds ratios (ORs) in our logistic regression model, we assigned 1 point each for male sex, hypertension, diabetes mellitus, left ventricular ejection fraction<40%, and PR interval >200 ms, 2 points for age >60 years, and 3 points for a previous history of AF. This resulted in a possible risk score from 0 to 10 points. We then tested the performance of the risk score by applying it to the validation cohort. All statistical analyses were conducted using R version 3.0 with the rms package, STATA v12, or SPSS v22.
Results
Baseline Patient Characteristics and Genotypes
Baseline patient characteristics for the discovery and validation cohorts are presented in Table 1 . In the discovery cohort of 556 patients without missing variables, mean age was 62±11 years, 72% were male, and 10% had a previous history of AF. In the validation cohort of 1164 patients, mean age was 64±10, 82% were male, and 4.3% had a previous history of AF.
Minor allele frequencies for the discovery and validation cohorts are presented in Table 2 . In the discovery cohort, rs10033464 (at 4q25) was not in Hardy-Weinberg equilibrium and was excluded from further analysis. In the validation cohort, rs6817105 at 4q25 and rs7164883 at 15q24 failed genotyping. Otherwise, all genotyping assays met prespecified quality control measures with >95% call rate and results were in Hardy-Weinberg equilibrium, and genotypes for each of the 10 SNPs were available for every patient included in the main analysis.
Risk Prediction Models for PoAF
PoAF during the index hospitalization after surgery, the primary study end point, occurred in 165 (30%) subjects in the discovery cohort. In the clinical-only model, variables significantly associated with PoAF included age (P<0.0001), longer PR interval (P=0.0006), and a previous history of AF (P<0.0001; Table 3 ). The largest effect size was seen with previous AF, with an OR of developing PoAF of 6.46 (95% confidence interval, 3.36-12.4). In the combined clinical and genetic model, age, PR interval, and previous AF remained statistically significant. However, none of the SNPs were
WHAT IS KNOWN
• Postoperative atrial fibrillation is a common and clinically important complication of cardiac surgery.
• Multiple common genetic risk variants are associated with ambulatory atrial fibrillation, but whether these also confer risk for postoperative atrial fibrillation is unknown.
WHAT THE STUDY ADDS
• We developed and externally validated a risk prediction model for postoperative atrial fibrillation.
• The model contained commonly available clinical variables and had good discrimination and calibration.
• Genetic variables did not improve the performance of our well-fitted clinical risk model. significantly associated with PoAF. ROC curves for both models showed good discrimination, with areas under the ROC curves of 0.763 and 0.78 in the clinical-only and combined clinical/genetic models, respectively (Figure A, red and blue curves). However, the difference between the models was not statistically significant (P=0.14 for difference in discrimination between the 2 models by likelihood ratio test).
The Vanderbilt Cardiac Surgery Registry clinical-only and combined clinical/genetic models were applied to the CABG Genomics validation cohort. The clinical-only model showed good discrimination, with an area under the ROC curve of 0.688 ( Figure A) . Application of the combined clinical/genetic model to the validation cohort resulted in a marginal improvement in discrimination (area under the ROC curve, 0.72; P=4.2×10 -6 for difference between the models). A calibration curve showed overall good calibration, though there was overprediction for the high probability groups, with lower-thanexpected actual probabilities of developing PoAF in groups who had the highest predicted probability ( Figure B ).
We derived a simple risk score for PoAF that included age >60 years, male sex, diabetes mellitus, hypertension, left ventricular ejection fraction<40%, PR interval >200 ms, and a previous history of AF. The score performed well in both the discovery and validation cohorts, with an incremental observed incidence of PoAF with increasing scores (χ 2 P<0.001 in both cohorts, Table 4 ).
Discussion
We developed and independently validated a clinical risk model for the prediction of PoAF. The model had good discrimination in the discovery and validation cohorts, with areas under the ROC curves of 0.76 and 0.69, respectively. We hypothesized that the addition of common AF risk SNPs to the model would improve discrimination. However, there was no difference between the clinical model and the combined clinical/genetic model in the discovery cohort, and only a marginal difference in the validation cohort. These findings call into question how much added value genetic information contributes to an already well-fitted model utilizing only clinical variables for the prediction of PoAF. Although SNPs in AF susceptibility genes have been independently associated with the common ambulatory forms of AF in multiple studies, our results suggest a limited role of these SNPs in predicting PoAF. One reason for this finding might be that the triggers for PoAF are primarily driven by clinical risk factors and common AF risk alleles do not have a significant impact on the incidence of PoAF, especially if only a limited number of genetic variables are considered. Alternatively, one or more of the SNPs we studied might be strongly associated with clinical predictors (especially prior history of AF), and, therefore, the predictive information of these SNPs might already be accounted for by the clinical factors in our model. PoAF is a common adverse event after cardiac surgery. In a large cohort of >18 000 patients undergoing cardiac surgery, the prevalence of PoAF was 19% and did not differ between on-pump and off-pump cases. 11 In another large multicenter Veterans Administration study, including >3800 patients, the overall incidence of PoAF was 30% and was the highest among patients undergoing CABG with mitral valve replacement (60%) and the lowest among patients having CABG without valve surgery (28%). 4 PoAF is an important predictor of morbidity and mortality. In a case-control study of >6400 patients who underwent CABG at a single center, PoAF was independently associated with stroke (OR, 2.0), in-hospital mortality (OR, 1.7), and long-term mortality (OR, 1.5). 17 The aforementioned Veterans Administration study found that PoAF was independently associated with stroke (OR, 2.2), heart failure (OR, 3.3), intensive care unit readmission (OR, 3.3), reintubation (OR, 4.3), in-hospital mortality (OR, 2.0), and 6-month mortality (OR, 2.2). 4 In a separate study of ≈6700 patients who underwent CABG, PoAF was associated with increased mortality at 1, 5, and 10 years after surgery. 18 Importantly, in the modern era of healthcare cost containment, the average length of stay for patients who developed PoAF in another study was increased by 4.9 days after full adjustment for covariates, corresponding to an increase in hospital cost of $10 055 per patient. 1 PoAF also predicted intensive care unit and hospital length of stay in a separate multicenter study (3.6 versus 2 days and 10 versus 7 days, respectively). 4 Multiple strategies for preventing PoAF have been studied, including therapy with β-blockers, antiarrhythmic drugs (AADs), magnesium, colchicine, atrial pacing, and posterior pericardiectomy. 19 Oral β-blockers have been consistently shown to reduce the development of PoAF and are recommended for virtually all patients undergoing cardiac surgery. 20 However, even with β-blockade, the incidence of PoAF remains high. Several studies have shown that prophylactic use of amiodarone or sotalol in the perioperative period reduces the incidence of the arrhythmia. In a meta-analysis of randomized trials, the OR (95% confidence interval) for development of PoAF for sotalol versus β-blocker was 0.42 (0.26-0.65) and for amiodarone versus placebo, it was 0.48 (0.4-0.57). 21 In fact, the use of amiodarone or sotalol for PoAF prophylaxis in selected patients has been recommended by the American College of Cardiology, 22 the American College of Chest Physicians, 23 and the Canadian Cardiovascular Society. 24 However, these recommendations have not been widely incorporated into clinical practice.
It is unclear why clinicians do not routinely use prediction tools and prophylactic strategies (other than use of β-blockers) to prevent PoAF after cardiac surgery. We and others have postulated that there is a reluctance to expose patients to the potential adverse effects of prophylactic AADs. 8 An individualized approach, whereby only high-risk patients are selected for perioperative use of AADs, might maximize benefits for these patients while minimizing the exposure of low-risk patients to the potential adverse drug effects. Thus, highly accurate methods of predicting which patients will develop PoAF are needed. However, to be widely accepted into clinical practice, prediction tools must also be simple to use. We therefore developed a simple risk score for the prediction of PoAF. The score performed well in our discovery cohort and also in our independent validation cohort. In both cohorts, a score ≥5 predicted a >40% risk of PoAF. Our score should assist clinicians in risk stratifying patients and identifying those who would benefit from additional preventative therapies such as prophylactic AADs.
Clinical risk factors for the development of PoAF, including age, hypertension, prior AF, heart failure, obesity, prolonged PR interval, tobacco use, and history of myocardial infarction, have been thoroughly studied. 1, 3, 4, [6] [7] [8] [9] [10] As a result, several risk assessment tools to predict PoAF have been developed. 3, 21 We previously conducted a multi-center study of the association of 4q25 SNPs with PoAF. 15 Seven 4q25 SNPs were independently associated with PoAF, and addition of 4q25 genotypes to a clinical risk prediction model improved discrimination (area under the ROC curve, 0.720 versus 0.702; P<0.0001). These data suggested that the addition of genetic information could improve the ability to identify patients at high risk for PoAF. However, we were not able to reproduce this finding in this study.
Our study has several important limitations that should be considered when interpreting the results. As with all retrospective studies, ours is prone to the effects of bias and unmeasured confounders. The final patient cohorts analyzed were selected from larger cardiac surgery registries based on the presence of complete data, and it is possible that our findings were affected by nonrandom missing variables. There were significant differences in clinical and genetic factors between the discovery and validation cohorts (Tables 1 and 2) that might account for the divergent results between the cohorts with regard to improved model performance with the addition of genetic factors. The definition of our primary end point, PoAF documented by 12 lead ECG or telemetry of sufficient duration to warrant specific therapy, was chosen to be consistent with previous studies. 1, 3, 5, 7, 11 However, use of a more precise definition (eg, PoAF of ≥5 minutes duration) might have led to different study results. To reduce variability, we chose a priori to limit our study to patients undergoing CABG without any concurrent procedures. However, excluding patients undergoing concurrent valve and structural procedures might limit the generalizability of our findings to broader patient populations.
In conclusion, we developed an accurate risk prediction model for PoAF in patients undergoing CABG based on readily available clinical variables. Importantly, we validated our model in a geographically independent cohort, a crucial step before any risk prediction model can be implemented in routine clinical practice. However, we were unable to prove our primary hypothesis that addition of AF susceptibility alleles would result in a clinically meaningful improvement in risk prediction model performance. Even in the current era of near ubiquitous use of postoperative β-blockers, the risk for the development of AF after cardiac surgery remains high. Other preventative strategies, including the use of AADs for selected high-risk patients, have been recommended but are seldom utilized. The ability to accurately identify patients at high risk for PoAF through the use of a prediction model should allow for an individualized approach wherein AADs, with their inherent potential toxicities, are used in patients who stand to benefit the most and avoided in others, potentially maximizing clinical benefits while reducing adverse drug reactions.
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